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Abstract
Background: Panic disorder (PD) is a serious DSM-IV axis I disorder affecting up to 3% of the
adult population each year. It is associated with a large burden of disease and extensive economic
costs. This study aims to examine the effects and feasibility of the 'Don't Panic' course, a preventive
cognitive behavioural intervention in sub-threshold and mild PD. It also compares the effectiveness
of two modifications of the course (8 vs. 12 sessions).
Methods: The method used was a quasi-experimental two-group pre-post design with a baseline
measurement (T0) and two follow-up measurements. Follow-ups were at the end of the
intervention (T1) and six months later (T2). Primary outcome measure was the Panic Disorder
Severity Scale-Self Report. A total of 114 participants suffering from panic attacks (mean age 42
years; 78% female) entered the study.
Results: The course participants showed a significant effect on the outcome measures at follow-
up. Large effect sizes were found on panic symptoms, on symptoms of agoraphobia and on mental
health-related quality of life at T1 and T2. Overall, the course leaders and the participants evaluated
the course positively. There were no significant differences in outcome measures between the
short and the long version of the course.
Conclusion: The study suggests that people with sub-threshold PD and mild PD could benefit
from this preventive intervention and that the intervention might be feasible. Furthermore, the
short version could be as effective as the long version.
Background
Panic disorder (PD), affecting 2% to 3% of the adult pop-
ulation each year [1,2], is associated with a large burden
of disease, considerable medical consumption and exten-
sive loss of productivity [3,4]. The incidence of PD is high
(about 35% of all cases each year of PD are new; [1]), indi-
cating the importance of prevention and early interven-
tion in PD.
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A substantial proportion of the population suffers from
sub-threshold PD [5,6]. Sub-threshold PD can be defined
as the presence of some symptoms of PD, not meeting the
DSM-IV diagnostic criteria. These subjects may be at risk
of developing full-blown PD [7].
Studies on prevention and early intervention in anxiety
disorders indicate that prevention of anxiety disorders
through cognitive-behavioural interventions can be suc-
cessful [8,9]. Only a few studies have been conducted on
the prevention of panic disorder [10,11]. The results of
these studies suggest that prevention of panic disorder is a
promising option.
As a pilot project we developed a preventive intervention
for adults with panic symptoms, called the 'Don't Panic'
course. The course is based on cognitive-behavioural prin-
ciples and makes use of interventions that have appeared
effective in the treatment of PD before [12,13].
The aim of this study was to examine the effects and feasi-
bility of the 'Don't Panic' course in a sample of self-
referred people suffering from panic attacks in an uncon-
trolled pilot study. In addition, the effectiveness of two
modifications of the course (8 vs. 12 sessions) was com-
pared.
Methods
Research design
We used a quasi-experimental two-group pre-post design
with a baseline measurement (T0), a post-test measure-
ment at the end of the course (T1) and a follow-up meas-
urement, 6 months after the course (T2). The study was
designed to mimic the Dutch health care system as natu-
ralistically as possible in terms of participant recruitment
and the manner in which intake, offering the interven-
tion, and monitoring outcomes are conducted. Because
the study simulates the usual practice in the Netherlands,
an ethical approval was not necessary.
Participants
Participants were recruited from the general population
through advertisements in regional newspapers and infor-
mation brochures at general practices. For screening, the
standard procedures employed by the Community Mental
Health Centres were used. Firstly, interested persons were
given more information about the course and underwent
initial screening by telephone to ascertain the presence of
panic symptoms. Secondly, potential participants had a
face-to-face clinical interview with a clinician (i.e., experi-
enced psychologist) from a Community Mental Health
Centre. The clinician used a list with inclusion and exclu-
sion criteria. Depending on the impression formed by the
clinicians, potential participants were included or
excluded. Those included in the study were people with
sub-threshold panic disorder or mild panic disorder with
or without additional agoraphobic problems (i.e., low
degree of symptom severity and little interference in work
or social functioning). Exclusion criteria were severe PD
(i.e., high degree of symptom severity and substantial
interference in work or social functioning), other current
psychiatric diagnoses or suicidality warranting treatment
or likely to interfere with participation in the group
course. People meeting one of the exclusion criteria were
advised to seek regular treatment. If a participant used
medication for anxiety or depression (e.g., anxiolytics or
antidepressants), it was agreed not to change the medica-
tion while attending the course. The participants were
receiving no other form of psychotherapy.
For the participants' flow through the study see Figure 1.
To join the study, the participant had to sign a written
informed consent. Fifty-four participants refused to take
part in the research (32%; mainly because they didn't feel
like it), but were allowed to attend the course.
A total of 114 participants were enrolled in the study and
completed the baseline measurements. In Table 1, the
characteristics of the course participants are presented.
A comparison of demographic and clinical status varia-
bles of the participants at baseline (T0) between the short
(N = 36) and the long (N = 78) version of the course dem-
onstrated no significant differences.
Measures
Primary outcome measure for panic and agoraphobic
symptoms was the self-report version of the Panic Disor-
der Severity Scale [14]. The Panic Disorder Severity Scale-
Self Report (PDSS-SR) has good psychometric properties
(Cronbach's alpha = 0.92; intraclass correlation coeffi-
cient = 0.81) [15]. Secondary outcomes for panic symp-
toms consisted of the Body Sensation Questionnaire
(BSQ1; [16]) and the subscale anxiety of the Symptom
Check-List (SCL-90; [17]). For symptoms of agoraphobia
the secondary outcomes were the Agoraphobic Cogni-
tions Questionnaire (ACQ; [16]) and the Mobility Inven-
tory (MI; [18]). In addition, the subscale phobic anxiety of
the SCL-90 [17] was used. For mental health-related qual-
ity of life, the outcome measure was the subscale mental
health  of the MOS Short-Form General Health Survey
(MOS-SF-20 Mh; [19]). To measure general symptoms of
depression, the subscale depression of the SCL-90 [17] was
used. Moreover, the Mastery-scale [20] was used to assess
locus of control. All scales have good psychometric prop-
erties [16-20]. Only on the MOS-SF-20 MH and the Mas-
tery-scale does a higher rating indicate a more favourable
outcome.BMC Research Notes 2009, 2:4 http://www.biomedcentral.com/1756-0500/2/4
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Questionnaires to evaluate the course were used at post-
test.
Intervention
The 'Don't Panic' course includes a course manual [21], to
be used by the clinician and prevention specialist offering
the intervention, as well as a participant workbook [22].
The course involves (a) psycho-education about the
nature and physiology of anxiety and panic attacks, (b)
changing life-style to enhance physical condition, (c)
stress management to prevent constant stress by learning
effective ways to cope with stressors, (d) relaxation train-
ing to reduce physiological arousal, (e) cognitive restruc-
turing to challenge and correct faulty beliefs regarding
panic and anxiety, (f) interoceptive exposure to reduce the
fear of somatic sensations, and (g) 'in vivo' exposure to
reduce avoidance of situations and use of safety behav-
iours. Furthermore, techniques aimed at relapse preven-
tion are taught. The short course consists of 8 weekly, two-
hour group sessions; the long version contains 12 weekly,
two-hour group sessions of 6 to 12 participants. Both ver-
sions have the same elements. The long version has more
sessions containing 'in vivo' exposure.
Procedure
Clinicians and prevention specialists from 12 community
mental health centres were trained in the selection proce-
dure of participants (e.g., using the inclusion and exclu-
sion criteria) and in using the course manual to conduct
the course. Integrity of intervention delivery was main-
tained by utilizing a structured and manual-based course
protocol.
Participants' flow through the study Figure 1
Participants' flow through the study. Note. PD = Panic Disorder.
Interested subjects and telephonic screening
n = 397 Other psychiatric symptoms
than panic symptoms
or practical restraints
(work, travelling) n = 136
Interview using inclusion and exclusion
criteria
n = 261
Contraindication by clinician n=93
(mainly: severe PD; other psychiatric 
problems), non-response n = 54
Intervention and participation in research 
after informed consent, pre-course data n = 114
Post-course data 
n = 91 (80%)
Follow-up data
n = 76 (67%)  BMC Research Notes 2009, 2:4 http://www.biomedcentral.com/1756-0500/2/4
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The twelve-session course was run by 9 centres and the 8
session course by 6 centres (3 centres offered both ver-
sions of the course; one mental health centre offered the
long version of the course four times. In these cases the
time between two courses was about two months and a
person participated in the course offered at the time the
person entered the study. There was no selection of partic-
ipants to the two versions of the course.). In total, the data
contains the results of 18 courses.
Data collection was conducted by an independent
research institute. Assessments consisted solely of self-
report measures through postal questionnaires and were
completed at home.
Statistical analyses
Analyses were conducted on an intention-to-treat basis.
The effect of the intervention was analysed with a
Repeated Measures ANOVA, Simple Contrast. Effect sizes
(d) were obtained by subtracting post-test (T1) or follow-
up (T2) means from baseline (T0) means and then divid-
ing the difference by the pooled standard deviation. The
categorization of Lipsey and Wilson [23] was used for
clinical interpretations of the d's.
The difference between the short and the long version of
the course on the severity of panic symptoms was ana-
lysed with a 2 Group (8 vs. 12 sessions) × 3 Time (base-
line, post-test, 6 month follow-up) Repeated Measures
ANOVA, with Group as the between-subject factor and
Time as within-subject factor. Levels of severity of panic
symptoms (PDSS-SR) constituted the dependent variable.
Wilks' lambda (λ) was used as multivariate criterion for
significance. The same analysis was performed on all the
other outcome measurements.
The significance level was set at α = 0.05, two-sided.
Results
Outcome
Table 2 presents an overview of the results on the meas-
urements. The course participants showed a significant
effect on the primary outcome measure and secondary
outcome measures at post-test and follow-up. Large effect
sizes were found on panic symptoms and on symptoms of
agoraphobia at T1 and T2. In addition, large effect sizes
were found on mental health-related quality of life at T1
and T2 and on depression at T2. The increase of internal
locus of control after the intervention showed medium
effect sizes. Effects remained stable from post-test to fol-
low-up.
The Repeated Measures ANOVAs on the outcome meas-
ures showed a significant effect of time, no significant
group effect between the short and the long version of the
course and no significant interaction effect for time ×
group (Table 3).
Medication use at baseline had no significant impact on
the residualized change scores at T1 on the primary out-
come measure (PDSS-SR; point-biserial correlation; r =
0.12, p = 0.249). For the other outcome measures at T1
(except for MOS-SF-20 Mh; point-biserial correlation; r =
-0.20, p = 0.029) and for all outcome measures at T2, the
results of the analyses were comparable.
Table 1: Characteristics of the course participants for Total Group, Short Version and Long Version
Total group (N = 114) Long version (N = 78) Short version (N = 36)
Female, N (%) 89 (78.1) 64 (82.1) 25 (69.4)
Mean age, Years (SD) 41.7 (11.4) 42.4 (11.4) 40.3 (11.5)
Married/living with partner, N (%) 87 (76.3) 58 (74.3) 29 (80.6)
Employed (paid), N (%) 85 (74.6) 56 (71.8) 29 (80.6)
Educational level, N (%)
Low 22 (19.3) 15 (19.2) 7 (19.4)
Middle 51 (44.7) 36 (46.2) 15 (41.7)
High 41 (36.0) 27 (34.6) 14 (38.9)
More than 1 year of panic complaints, N (%) 95 (83.3) 65 (83.3) 30 (83.3)
Medication for anxiety or depression, N (%) 64 (56.1) 42 (53.8) 22 (61.1)
SCL-90 Anx, M (SD) (range: 0–4) 1.26 (0.72) 1.31 (0.76) 1.15 (0.63)
SCL-90 Pho, M (SD) (range: 0–4) 1.13 (0.83) 1.16 (0.84) 1.09 (0.81)
SCL-90 Dep, M (SD) (range: 0–4) 0.89 (0.62) 0.89 (0.63) 0.88 (0.61)
PDSS-SR, M (SD)* (range: 0–28) 8.7 (5.0) 8.8 (5.5) 8.6 (4.1)
Subclinical (score 0–7), N (%) 36 (40.4) 25 (47.2) 11 (30.6)
Clinical (score 8–28), N (%) 53 (59.6) 28 (52.8) 25 (69.4)
Note. SCL-90 = Symptom Check-List: Anx = anxiety, Pho = phobic anxiety, Dep = depression; PDSS-SR = Panic Disorder Severity Scale-Self Report.
* based on n = 89 (the PDSS-SR was not used on the first 3 courses).BMC Research Notes 2009, 2:4 http://www.biomedcentral.com/1756-0500/2/4
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Feasibility and acceptability
After each session the prevention specialists registered all
the participants attending, and ascertained whether they
had done their homework. On the basis of this informa-
tion, the dropout rate (participants who indicated stop-
ping the course, mainly because of work obligations or
illness) was 13%; the mean number of attended sessions
for the short version was 6.4 sessions (80%) and for the
long version 9.0 sessions (75%). Of the participants
attending a session, on average 91% had completed their
homework. Therefore, compliance with the intervention
was satisfactory.
The participants evaluated the course positively (organiza-
tional aspects, coaching, content, group sessions, and
workbook). Asked whether the course had contributed to
being more able to manage anxiety, 98% answered in the
Table 2: Means, Standard Deviations, Repeated Measures ANOVA, Simple Contrast and (range) Effect Sizes (d) for Baseline (T0), 
Post-test (T1), and Follow-up (T2) (N = 114)
Scale measure T0 Mean (SD) T1 Mean (SD) T2 Mean (SD) Effect Size (d)
T0-T1
Range
(d) (T0-T1)
Effect Size (d)
T0-T2
Range
(d) (T0-T2)
PDSS-SR* 8.74 (4.98) 5.03** (4.98) 5.07** (5.39) 0.75 -1.9–2.8 0.71 -3.1–3.2
(range: 0–28)
BSQ1 2.04 (0.62) 1.47** (0.49) 1.42** (0.60) 1.02 -1.0–5.3 1.02 -1.7–3.6
(range: 1–5)
ACQ 2.00 (0.66) 1.47** (0.60) 1.42** (0.56) 0.84 -0.8–3.6 0.95 -1.5–3.1
(range: 1–5)
MI 2.15 (0.78) 1.65** (0.73) 1.61** (0.60) 0.66 -1.6–3.5 0.77 -2.8–3.5
(range: 1–5)
SCL-90 Anx 1.26 (0.72) 0.68** (0.64) 0.62** (0.60) 0.84 -1.1–4.4 0.96 -2.1–4.4
(range: 0–4)
SCL-90 Pho 1.13 (0.83) 0.63** (0.72) 0.50** (0.60) 0.64 -1.7–3.9 0.88 -2.1–3.9
(range: 0–4)
SCL-90 Dep 0.89 (0.62) 0.56** (0.59) 0.51** (0.57) 0.55 -1.2–3.2 0.63 -3.8–3.4
(range: 0–4)
MOS-SF-20
Mh
57.60 (16.43) 67.95** (17.09) 68.76** (18.38) 0.62 -1.7–2.7 0.64 -1.5–2.9
(range: 0–
100)
MASTERY* 17.47 (4.21) 18.91** (3.93) 19.11** (4.32) 0.35 -1.6–3.1 0.38 -1.8–2.7
(range: 5–25)
Note. PDSS-SR = Panic Disorder Severity Scale-Self Report; BSQ1 = Body Sensation Questionnaire; ACQ = Agoraphobic Cognitions 
Questionnaire, total score; MI = Mobility Inventory, total score; SCL-90 = Symptom Check-List: Anx = anxiety; Pho = phobic anxiety; Dep = 
depression; MOS-SF-20 = Medical Outcomes Study Short-Form General Health Survey (SF-20): Mh = mental health.
* based on n = 89 (the PDSS-SR and MASTERY were not used on the first 3 courses).
** Repeated Measures ANOVA, Simple Contrast p < 0.001.
Table 3: Repeated Measures ANOVA on the outcome measures by group (N = 114)
Scale Intervention (time) effect Group (condition) effect Interaction effect for intervention × group
measure F and pF   and pF  and p
PDSS-SR* F (2, 86) = 28.321, p = <0.001 F (1, 87) = 0.086, p = 0.861 F (2, 86) = 0.112, p = 0.926
BSQ1 F (2, 111) = 66.789, p = <0.001 F (1, 112) = 0.059, p = 0.820 F (2, 111) = 0.899, p = 0.612
ACQ F (2, 111) = 58.273, p = <0.001 F (1, 112) = 0.019, p = 0.914 F (2, 111) = 0.578, p = 0.734
MI F (2, 111) = 39.805, p = <0.001 F (1, 112) = 0.415, p = 0.527 F (2, 111) = 0.926, p = 0.605
SCL-90 Anx F (2, 111) = 45.702, p = <0.001 F (1, 112) = 0.148, p = 0.743 F (2, 111) = 1.206, p = 0.491
SCL-90 Pho F (2, 111) = 33.398, p = <0.001 F (1, 112) = 0.084, p = 0.842 F (2, 111) = 0.722, p = 0.650
SCL-90 Dep F (2, 111) = 22.132, p = <0.001 F (1, 112) = 0.082, p = 0.849 F (2, 111) = 0.411, p = 0.768
MOS-SF-20 Mh F (2, 111) = 31.287, p = <0.001 F (1, 112) = 0.246, p = 0.646 F (2, 111) = 0.721, p = 0.633
MASTERY* F (2, 86) = 11.400, p = <0.009 F (1, 87) = 2.054, p = 0.168 F (2, 86) = 0.453, p = 0.747
Note. PDSS-SR = Panic Disorder Severity Scale-Self Report; BSQ1 = Body Sensation Questionnaire; ACQ = Agoraphobic Cognitions 
Questionnaire, total score; MI = Mobility Inventory, total score; SCL-90 = Symptom Check-List: Anx = anxiety; Pho = phobic anxiety; Dep = 
depression; MOS-SF-20 = Medical Outcomes Study Short-Form General Health Survey (SF-20): Mh = mental health.
* based on n = 89 (the PDSS-SR and MASTERY were not used on the first 3 courses).BMC Research Notes 2009, 2:4 http://www.biomedcentral.com/1756-0500/2/4
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affirmative. Of the participants, 92% were "satisfied" or
"very satisfied" with the course.
Overall, the course leaders also evaluated the course posi-
tively (content, time schedule, didactic elements). These
findings suggest the intervention is feasible and accepta-
ble.
Discussion
In this study, the participants in the preventive course
'Don't Panic' showed a significant reduction in panic and
agoraphobic symptoms after the course. Large effect sizes
were achieved in reducing panic and agoraphobic symp-
toms. The improvement was maintained over 6 months
after the intervention. The results suggest that the course is
acceptable and feasible. These findings converge with the
findings of earlier research on the prevention of panic dis-
order [10,11].
Furthermore, symptoms of depression declined, as meas-
ured by the SCL-90. In addition, the internal locus of con-
trol and the quality of life increased significantly. These
findings are important because people with panic symp-
toms may also have higher rates of other psychiatric
symptoms [24].
We did not find any significant differences in outcome
measures between the short and the long version of the
course. A lack of power may play a role in this finding.
There are several limitations to the present study. Firstly,
it lacked a structured psychiatric interview. Therefore, it is
unclear how many participants might have been diag-
nosed with panic disorder or other psychiatric disorders at
baseline, post-test and follow-up. Furthermore, the diag-
nosis of agoraphobia might have clarified whether it had
an impact on the results.
Secondly, 56% of the participants used medication for
anxiety or depression at baseline. Although medication
use at baseline did not predict outcome, continued use of
medication may have hampered the effect of the interven-
tion. This is because medication may have been used as a
safety behaviour. Likewise, discontinuation of medication
after psychological treatment may also have reduced treat-
ment efficacy because patients may attribute the symptom
reduction achieved to the use of medication and may lack
self-confidence in being able to control their panic attacks
themselves. In the absence of data on medication use after
baseline assessment, the possible interactions of medica-
tion use with psychological treatment remain unknown.
Thirdly, the present study did not include a control group.
Thus, it is not certain whether the effects found in this
study were due to the preventive course.
Fourthly, the study did not account for possible differ-
ences in outcome between the 12 community mental
health centres which offered the course.
Fifthly, because the intervention is multi-component, it
cannot be known which of the components may have
been effective.
Finally, the results may be biased if people of the intended
target population who did not participate in the course or
participated in the course, but not in the study, differed
from those who did.
Conclusion
People with sub-threshold PD and mild PD may benefit
from a preventive group intervention. The short version is
as effective as the long version, but is likely to be associ-
ated with fewer costs and greater acceptability. Future,
randomized, controlled trials using diagnostic assess-
ments are needed to confirm the present findings.
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